Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on December 5, 2017. The filing serves as a Regulation FD disclosure regarding the presentation of clinical trial data at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the public presentation of additional safety, efficacy, and tolerability data from an exploratory Phase 2 clinical trial. The trial examined the efficacy of the Company's neurogenic compound, NSI-189, at a dosage of 40 mg twice daily (BID) compared to placebo for the treatment of major depressive disorder in out-patients.
Guidance, Outlook, and Risks
- Management Commentary: The Company announced the data presentation via a press release and a poster exhibit attached to the filing.
- Regulatory Status: The information contained in this Item 7.01 and its exhibits is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
- Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties of clinical trial data interpretation.
Investor Verification Checklist
- Verify the specific statistical outcomes and safety profile details in the attached poster (Exhibit 99.02) and press release (Exhibit 99.01).
- Confirm the Company's name is Neuralstem, Inc., as the input metadata reference to "Palisade Bio, Inc." appears to be incorrect based on the filing text.
- Review subsequent filings to determine if the Phase 2 data influenced the Company's strategic direction or future trial designs.
- Note that this 8-K does not contain financial data; refer to the most recent 10-Q or 10-K for financial health metrics.